Topic:

M&A

Latest Headlines

Latest Headlines

Roche snags a genomics startup with an eye on cancer R&D

Roche bought up a Stanford University-founded upstart with a promising approach to tracking the spread of cancer, eyeing a new tool in its expansive oncology R&D efforts.

Mylan seeks entry into animal health via $29B bid for Perrigo

When Mylan offered to buy Perrigo for $205 per share last Wednesday, the brewing $29 billion bid was hailed as the giant generics deal Wall Street has been anticipating. But this deal has an animal health angle too: If Mylan pulls it off, the acquisition will mark its entry into the veterinary market.

Will Mylan's $29B bid spur other Perrigo suitors to enter the fray?

More than a couple of analysts agree that there may be a company out there that's after Mylan--and that that could have prompted the company's $28.9 billion bid for Ireland's Perrigo. But now that Mylan's made its offer, could that spur other Perrigo offers, too?

Was Mylan's $29B Perrigo bid a takeover defense? Analysts say yes

Since Mylan went public on Wednesday with a $205-per-share buyout offer for Ireland's Perrigo, analysts have been weighing the pros and cons of a tie-up between the two generics makers. But there's one thing at least a few of them agree on: The $29 billion bid has to be a response to other M&A action going on behind the scenes.

Protea buys CRO vivoPharm for preclinical expertise

West Virginia bioanalytics outfit Protea Biosciences has acquired preclinical researcher vivoPharm to expand in the world of early-stage oncology development.

Catalent reaches into Australia with latest buyout

Catalent is buying a drug packaging operation in Australia, extending its global reach with a focus on the Asia-Pacific region.

Mylan makes a pass at Perrigo with $205-per-share buyout offer

Generics specialist Mylan has zeroed in on the big buyout everyone's been waiting for. The Pittsburgh-based drugmaker offered $205 per share for Perrigo, the over-the-counter drugmaker that just closed its own $4.5 billion deal for Belgium's Omega Pharma.

Rhythm rolls into Phase IIb with an Actavis buyout in the balance

Boston biotech Rhythm is advancing its lead drug into Phase IIb under the eye of Actavis, which has inked a deal to buy the gastrointestinal treatment if it likes what it sees.

Watch out, Valeant. Concordia's joining the buy-to-grow pharma business

Serial acquirer Valeant may have a mini-me in Concordia Healthcare--but it's a mini-me that could just wind up luring investors away from the Quebec-based drugmaker.

Why didn't J&J buy Imbruvica partner Pharmacyclics? It wants hot drugs cheap, CEO says

Why didn't Johnson & Johnson buy Pharmacyclics? Good question--and one The Wall Street Journal posed to CEO Alex Gorsky in a recent interview in Tokyo.